ArticleMolecular therapy : the journal of the American Society of Gene Therapy2010
Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- The Bioengineering of Insect Cell Lines for Biotherapeutics and Vaccine Production: An Updated Review.Vaccines · 2025Review
- Review
- The Magic Staff: A Comprehensive Overview of Baculovirus-Based Technologies Applied to Human and Animal Health.Viruses · 2022Review
- Identification of the Key Functional Domains ofInternational journal of molecular sciences · 2022Article
- Highly efficient CRISPR-mediated large DNA docking and multiplexed prime editing using a single baculovirus.Nucleic acids research · 2022Article
- Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies.Applied microbiology and biotechnology · 2021Review
- Baculoviruses in Gene Therapy and Personalized Medicine.Biologics : targets & therapy · 2021Review
- Unraveling the Genome-Wide Impact of Recombinant Baculovirus Infection in Mammalian Cells for Gene Delivery.Genes · 2020Article
- DAF-shielded baculovirus-vectored vaccine enhances protection against malaria sporozoite challenge in mice.Malaria journal · 2017Article
- Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials.Molecular therapy. Methods & clinical development · 2016Review
- Review
- Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo.Journal of virology · 2013Article
- Baculovirus: an insect-derived vector for diverse gene transfer applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Review
- Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization.Scientific reports · 2013Article
- Article
- Baculovirus vectors for antiangiogenesis-based cancer gene therapy.Cancer gene therapy · 2011Article
- Non-human viruses developed as therapeutic agent for use in humans.Reviews in medical virology · 2011Review
- Baculovirus expression systems for production of recombinant proteins in insect and mammalian cells.Molecular biology · 2011Article
- Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells.Cellular & molecular immunology · 2010Article
- Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the major obstacles in the use of baculovirus vectors for in vivo gene transfer is the virus inactivation by serum complement. In this study, we investigated the effect of decay-accelerating factor (DAF), factor H (FH)-like protein-1 (FHL-1), C4b-binding protein (C4BP), and membrane cofactor protein (MCP) on protection of baculovirus vectors from the complement-mediated inactivation. Complement regulatory proteins were displayed on baculovirus surface as fusions to membrane anchor of the vesicular stomatitis virus-G (VSV-G) protein. This strategy resulted in abundant expression of recombinant proteins on the viral envelope while viral titers comparable to control virus were reached. The surface-modified vectors exhibited complement resistance in vitro, DAF showing the highest level of protection. Intraportal delivery of DAF-displaying baculovirus resulted in increased survival and enhanced gene expression in immunocompetent mice. Mice receiving DAF-displaying baculovirus also exhibited lower level of liver inflammation as evidenced by aspartate aminotransferase (AST). In line with this, macrophages treated with DAF baculovirus produced lower levels of inflammatory cytokines IL-1beta, IL-6, and IL-12p40 compared to control virus. These results suggest that DAF-display can protect the vector against complement inactivation but also reduce complement-mediated inflammation injury. In conclusion, complement shielded baculovirus vectors represent attractive tools for effective in vivo gene delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.